DNLI Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

20.450

Open

19.700

VWAP

20.11

Vol

574.24K

Mkt Cap

3.13B

Low

19.680

Amount

11.55M

EV/EBITDA(TTM)

Total Shares

158.59M

2.27B

EV/OCF(TTM)

P/S(TTM)

Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases. It has developed a technology, called the TransportVehicle (TV), to address the BBB challenge. Its advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (MPS II or Hunter syndrome). Its TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo syndrome) and DNL593 (PTV:PGRN) for frontotemporal dementia-granulin (FTD-GRN). Its small-molecule clinical development portfolio includes BIIB122/DNL151 (small molecule LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (small molecule eIF2B activator) for amyotrophic lateral sclerosis (ALS). It is also exploring programs in oncology, inflammation, and other diseases.

Events Timeline

(ET)

2026-01-06

08:30:00

Denali Therapeutics Announces Key Milestones and Priorities for 2026

2025-12-30 (ET)

2025-12-30

08:20:00

Denali Therapeutics Publishes Hunter Syndrome Therapy Trial Results

2025-12-10 (ET)

2025-12-10

06:10:00

Goldman Sachs and Others Manage IPO Deal Range of $17.00-$18.00

News

9.5

03-09Benzinga

Relmada Therapeutics Shares Surge 40.8% on Promising Trial Data

9.0

03-06CNBC

FDA Rejects Multiple Experimental Drug Applications, Raising Investor Concerns

7.0

03-06Newsfilter

FDA Drug Approval Uncertainty Intensifies

8.5

02-26seekingalpha

Denali Therapeutics Reports Q4 Results and Stock Offering

8.5

02-19Globenewswire

Shifting Trends in Biotechnology Mergers and Acquisitions

9.0

02-10Newsfilter

REGENXBIO Faces FDA Challenges for Gene Therapy Approval

10 Analyst Rating

Wall Street analysts forecast DNLI stock price to rise

10 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

25.00

Averages

32.78

High

40.00

Current: 0.000

Low

25.00

Averages

32.78

High

40.00

BTIG

Buy

maintain

$32 -> $36

AI Analysis

2026-03-02

Reason

BTIG

Price Target

$32 -> $36

AI Analysis

2026-03-02

maintain

Buy

Reason

BTIG raised the firm's price target on Denali Therapeutics to $36 from $32 and keeps a Buy rating on the shares. The company has established a clear path to get complex drugs approved and can now leverage their expertise and the quality FDA relationship they have built to fast-track the pipeline, the analyst tells investors in a research note.

Stifel

Paul Matteis

Buy

downgrade

$37 -> $34

2026-02-27

Reason

Stifel

Paul Matteis

Price Target

$37 -> $34

2026-02-27

downgrade

Buy

Reason

Stifel analyst Paul Matteis lowered the firm's price target on Denali Therapeutics to $34 from $37 and keeps a Buy rating on the shares.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for DNLI

Unlock Now

Valuation Metrics

The current forward P/E ratio for Denali Therapeutics Inc (DNLI.O) is -5.51, compared to its 5-year average forward P/E of -12.20. For a more detailed relative valuation and DCF analysis to assess Denali Therapeutics Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-12.20

Current PE

-5.51

Overvalued PE

-3.68

Undervalued PE

-20.72

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-9.18

Current EV/EBITDA

-3.14

Overvalued EV/EBITDA

-1.59

Undervalued EV/EBITDA

-16.77

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

71.68

Current PS

199.57

Overvalued PS

121.28

Undervalued PS

22.08

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

any good trades for today

Intellectia · 40 candidates

Price: $5.00 - $100.00Volume: >= 1,000,000Price Change Pct: $3.00 - $15.00Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20

Ticker

Name

Market Cap$

DYN

Dyne Therapeutics Inc

2.45B

AXTI

AXT Inc

1.79B

SLDB

Solid Biosciences Inc

525.89M

CAPR

Capricor Therapeutics Inc

1.52B

ICL

ICL Group Ltd

6.38B

TALK

Talkspace Inc

788.52M

Strongest buys

Intellectia · 54 candidates

Market Cap: >= 2.00BAnalyst Consensus: Strong BuyList Exchange: XNYS, XNAS, XASETarget Price Upside Potential: MoreAbovePriceMoving Average Relationship: PriceAboveMA200Monthly Average Dollar Volume: >= 500,000

Ticker

Name

Market Cap$

HSAI

Hesai Group

3.73B

RIOT

Riot Platforms Inc

5.75B

SYRE

Spyre Therapeutics Inc

2.48B

IMVT

Immunovant Inc

5.24B

EWTX

Edgewise Therapeutics Inc

2.98B

NUVL

Nuvalent Inc

7.99B

Exploding stocks

Intellectia · 10 candidates

Market Cap: >= 1000.00MRelative Vol: >= 1.50Beta: HighRiskWeek Price Change Pct: >= $5.00Month Price Change Pct: >= $20.00Monthly Average Dollar Volume: >= 500,000

Ticker

Name

Market Cap$

STX

Seagate Technology Holdings PLC

88.88B

ALGM

Allegro Microsystems Inc

6.83B

DNLI

Denali Therapeutics Inc

3.39B

MOD

Modine Manufacturing Co

9.72B

ACMR

ACM Research Inc

3.77B

MBIN

Merchants Bancorp

1.90B

best strong buy for today

Intellectia · 86 candidates

Analyst Consensus: Strong BuyList Exchange: XNYS, XNAS, XASETarget Price Upside Potential: MoreAbovePriceMoving Average Relationship: PriceAboveMA20One Day Rise Prob: >= 55Monthly Average Dollar Volume: >= 500,000

Ticker

Name

Market Cap$

CING

Cingulate Inc

43.41M

CATX

Perspective Therapeutics Inc

261.77M

ELVN

Enliven Therapeutics Inc

1.51B

ADTN

ADTRAN Holdings Inc

757.90M

UTI

Universal Technical Institute Inc

1.52B

CNTA

Centessa Pharmaceuticals PLC

3.82B

best moving stock right now

Intellectia · 16 candidates

Market Cap: >= 2.00BRegion: USPrice: >= $5.00Volume: >= 2,000,000Price Change Pct: >= $5.00List Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

LBRT

Liberty Energy Inc

3.50B

VIAV

Viavi Solutions Inc

4.74B

LUV

Southwest Airlines Co

21.63B

RCL

Royal Caribbean Cruises Ltd

81.36B

TAL

TAL Education Group

6.55B

ALGM

Allegro Microsystems Inc

6.40B

entonces que acciones?

Intellectia · 74 candidates

Market Cap: >= 3.00BRsi Category: moderateWeek Price Change Pct: $5.00 - $20.00Ema 20: >= -100Ema 60: >= -100Monthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

SSL

Sasol Ltd

4.76B

LMND

Lemonade Inc

6.97B

TEO

Telecom Argentina SA

5.50B

SBS

Companhia de Saneamento Basico do Estado de Sao Paulo - SABESP

18.55B

KEP

Korea Electric Power Corp

27.73B

PKX

Posco Holdings Inc

19.18B

which stock should i buy, for quick return

Intellectia · 54 candidates

Market Cap: 1000.00M - 8.00BRelative Vol: >= 1.30Beta: HighRiskEarnings Surprise: EpsBeatWeek Price Change Pct: >= $0.00

Ticker

Name

Market Cap$

AutoNation Inc

8.00B

CMPO

Composecure Inc

7.43B

CAMT

Camtek Ltd

6.70B

FORM

FormFactor Inc

6.47B

LMND

Lemonade Inc

6.38B

RIG

Transocean Ltd

5.10B

US MARKETS , ALL SECTORS

Intellectia · 158 candidates

Dividend Yield Ttm: >= 0Debt Equity: <= 1Pe Ttm: <= 10

Ticker

Name

Market Cap$

QXO

QXO Inc

15.83B

BMNR

Bitmine Immersion Technologies Inc

13.35B

CGON

CG Oncology Inc

4.61B

SOUN

SoundHound AI Inc

4.46B

ACLX

Arcellx Inc

3.98B

CALM

Cal-Maine Foods Inc

3.79B

Whales Holding DNLI

Crestline Investors Inc.

Bluebox Asset Management Uk Ltd.

Cercano Management LLC

Baker Bros. Advisors LP

Trading Trends

People Also Watch

Frequently Asked Questions

What is Denali Therapeutics Inc (DNLI) stock price today?

The current price of DNLI is 20.19 USD — it has increased 2.23

What is Denali Therapeutics Inc (DNLI)'s business?

What is the price predicton of DNLI Stock?

Wall Street analysts forecast DNLI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DNLI is32.78 USD with a low forecast of 25.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Denali Therapeutics Inc (DNLI)'s revenue for the last quarter?

Denali Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased

What is Denali Therapeutics Inc (DNLI)'s earnings per share (EPS) for the last quarter?

Denali Therapeutics Inc. EPS for the last quarter amounts to -0.73 USD, increased 8.96

How many employees does Denali Therapeutics Inc (DNLI). have?

Denali Therapeutics Inc (DNLI) has 503 emplpoyees as of March 20 2026.

What is Denali Therapeutics Inc (DNLI) market cap?

Today DNLI has the market capitalization of 3.13B USD.

DNLI Overview

DNLI Overview

Events Timeline

News

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Related Community Screener

Whales Holding DNLI

Trading Trends

People Also Watch

Frequently Asked Questions

What is Denali Therapeutics Inc (DNLI) stock price today?

What is Denali Therapeutics Inc (DNLI)'s business?

What is the price predicton of DNLI Stock?

What is Denali Therapeutics Inc (DNLI)'s revenue for the last quarter?

What is Denali Therapeutics Inc (DNLI)'s earnings per share (EPS) for the last quarter?

How many employees does Denali Therapeutics Inc (DNLI). have?

What is Denali Therapeutics Inc (DNLI) market cap?